Literature DB >> 6759392

Vascular wall renin in spontaneously hypertensive rats. Potential relevance to hypertension maintenance and antihypertensive effect of captopril.

M M Asaad, M J Antonaccio.   

Abstract

Relationships among systolic blood pressure (SBP), plasma renin activity (PRA), arterial renin concentrations (ARC), and venous renin concentrations (VRC) were examined in spontaneously hypertensive rats (SHR) and normotensive Wistar-Kyoto (WKY) rats before and after treatment with captopril. The ARC was elevated in SHR relative to WKY whereas VRC was not. Similarly, ARC was related to SBP (r = 0.69, p less than 0.01) whereas PRA was not (r = 0.04). Captopril (100 mg/kg daily by mouth for 8 days) decreased blood pressure significantly in both SHR and WKY. PRA as well as ARC and VRC were all increased by captopril. Bilateral nephrectomy virtually eliminated PRA but ARC was not significantly reduced over a 24-hour period. Bilateral nephrectomy also markedly attenuated the acute antihypertensive effects of captopril in SHR; however, a modest effect was still apparent. It is suggested that ARC in SHR, being higher than in WKY, may play a role in the genesis or maintenance of hypertension in this model. Furthermore, the effects of captopril in both intact and nephrectomized SHR may be related to the ability of captopril to inhibit the vascular formation of angiotensin II. Finally, vascular renin is probably not renal in origin and responds to typical feedback inhibition as unmasked by captopril administration.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6759392     DOI: 10.1161/01.hyp.4.4.487

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  14 in total

1.  Effects of acute and chronic cilazapril treatment in spontaneously hypertensive rats.

Authors:  W Fischli; F Hefti; J P Clozel
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

Review 2.  Newer ACE inhibitors. A look at the future.

Authors:  A Salvetti
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

3.  Expression of the renin gene in extra-renal tissues of the rat.

Authors:  N J Samani; J D Swales; W J Brammar
Journal:  Biochem J       Date:  1988-08-01       Impact factor: 3.857

4.  Induction of the proto-oncogene c-jun by angiotensin II.

Authors:  A J Naftilan; G K Gilliland; C S Eldridge; A S Kraft
Journal:  Mol Cell Biol       Date:  1990-10       Impact factor: 4.272

5.  Effects of fosinopril on renal function, baroreflex response and noradrenaline pressor response in conscious normotensive dogs.

Authors:  C Buranakarl; A Kijtawornrat; P Nampimoon
Journal:  Vet Res Commun       Date:  2001-07       Impact factor: 2.459

Review 6.  Inhibitors of the angiotensin I converting enzyme as antihypertensive drugs.

Authors:  P A Van Zwieten; A De Jonge; P B Timmermans
Journal:  Pharm Weekbl Sci       Date:  1983-10-21

7.  Angiotensin-converting enzyme labeled with [3H]captopril. Tissue localizations and changes in different models of hypertension in the rat.

Authors:  S K Wilson; D R Lynch; S H Snyder
Journal:  J Clin Invest       Date:  1987-09       Impact factor: 14.808

8.  Inhibition of Autophagy by Captopril Attenuates Prion Peptide-Mediated Neuronal Apoptosis via AMPK Activation.

Authors:  Ji-Hong Moon; Jae-Kyo Jeong; Jeong-Min Hong; Jae-Won Seol; Sang-Youel Park
Journal:  Mol Neurobiol       Date:  2018-10-05       Impact factor: 5.590

9.  Humoral and haemodynamic effects of idrapril calcium, the prototype of a new class of ACE-inhibitors, in essential hypertensive patients.

Authors:  S Taddei; L Ghiadoni; P Mattei; I Sudano; P Duranti; S Favilla; A Virdis; A Romagnoli; M Criscuoli; A Coppini
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

10.  Cardiovascular effects of GR117289, a novel angiotensin AT1 receptor antagonist.

Authors:  A Hilditch; A A Hunt; C J Gardner; D J Twissell; J Polley; A Travers; G M Drew; D Middlemiss; B C Ross; M J Robertson
Journal:  Br J Pharmacol       Date:  1994-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.